MedPage Today August 30, 2024
— Non-cardiovascular benefits observed in SELECT trial
LONDON — The clinical benefits of semaglutide (Wegovy) went beyond expectations in the SELECT trial, given the reductions in non-cardiovascular and infectious disease deaths observed.
Among people with overweight or obesity and pre-existing cardiovascular disease, the drop in all-cause deaths associated with weekly semaglutide injections versus placebo (4.3% vs 5.2%, HR 0.81, 95% CI 0.71-0.93) was broken down to a nonsignificant trend toward less cardiovascular death (2.5% vs 3.0%, HR 0.85, 95% CI 0.71-1.01) while non-cardiovascular deaths were significantly reduced (1.7% vs 2.2%, HR 0.77, 95% CI 0.62-0.95).
Notably, the lower rate of non-cardiovascular mortality was driven by a reduction in infectious deaths (HR 0.71, 95% CI 0.51-0.98) — in particular COVID-19-related deaths...
Today's Sponsors
Today's Sponsor